A5037241642- Gastrointestinal Tumor Research and Treatment
- Gastrointestinal disorders and treatments
- Sarcoma Diagnosis and Treatment
- Gastric Cancer Management and Outcomes
- Ferroptosis and cancer prognosis
- Viral Infections and Immunology Research
- Epigenetics and DNA Methylation
- RNA and protein synthesis mechanisms
- Molecular Biology Techniques and Applications
- Virus-based gene therapy research
- Metastasis and carcinoma case studies
- Peptidase Inhibition and Analysis
- Chronic Myeloid Leukemia Treatments
- Cell death mechanisms and regulation
- Traumatic Brain Injury and Neurovascular Disturbances
- Cancer-related molecular mechanisms research
- RNA modifications and cancer
- Lung Cancer Treatments and Mutations
- Radiomics and Machine Learning in Medical Imaging
- Angiogenesis and VEGF in Cancer
- Renal cell carcinoma treatment
- Histone Deacetylase Inhibitors Research
- HER2/EGFR in Cancer Research
- Gene expression and cancer classification
- Neurofibromatosis and Schwannoma Cases
Tang Du Hospital
2024
Air Force Medical University
1999-2024
Xinjiang University
2022-2023
Deciphera Pharmaceuticals (United States)
2018-2022
Jilin University
2020-2022
China Medical University
2020
Xian Central Hospital
2018
Capital Medical University
2018
China Railway Group (China)
2018
Doylestown Hospital
2013
PURPOSE Sunitinib, a multitargeted tyrosine kinase inhibitor (TKI), is approved for advanced gastrointestinal stromal tumor (GIST) after imatinib failure. Ripretinib switch-control TKI GIST prior treatment with three or more TKIs, including imatinib. We compared efficacy and safety of ripretinib versus sunitinib in patients who were previously treated (INTRIGUE, ClinicalTrials.gov identifier: NCT03673501 ). PATIENTS AND METHODS Random assignment was 1:1 to once-daily 150 mg 50 (4 weeks on/2...
In advanced gastrointestinal stromal tumor (GIST), there is an unmet need for therapies that target both primary and secondary mutations of pathogenic KIT/PDGFRA oncoproteins. Ripretinib a novel switch-control kinase inhibitor designed to inhibit wide range
Abstract Purpose: Most patients with gastrointestinal stromal tumor (GIST) have activating mutations in KIT/PDGFRA and are initially responsive to tyrosine kinase inhibitors (TKI). The acquisition of secondary leads refractory/relapsed disease. This study reports the results an analysis from phase III INVICTUS (NCT03353753) characterizing genomic heterogeneity tumors advanced GIST evaluating ripretinib efficacy across mutation subgroups. Patients Methods: Tumor tissue liquid biopsy samples...
359881 Background: Sunitinib is approved for advanced gastrointestinal stromal tumor (GIST) after imatinib failure. Ripretinib, a broad-spectrum KIT and PDGFRA switch-control tyrosine kinase inhibitor (TKI), indicated the treatment of adult patients (pts) with GIST who received prior 3 or more TKIs, including imatinib. We compared efficacy safety ripretinib vs sunitinib in pts progressed on were intolerant to Methods: This multicenter, global, randomized, open-label phase study (NCT03673501)...
Guanine nucleotide-binding protein-like 3-like protein (GNL3L) is a novel, evolutionarily conserved, GTP-binding nucleolar protein. This study aimed to investigate the expression, prognosis, and immune value of GNL3L in pan-cancer from multiple omics analyses. Firstly, expression prognostic were discussed using TIMER2 database, GEPIA cBioportal COX regression analysis, enrichment analysis. The association with tumor mutational burden (TMB), microsatellite instability (MSI), mismatch repair...
Hand, foot, and mouth disease (HFMD) is a febrile exanthematous with typical or atypical symptoms. Typical HFMD usually caused by enterovirus 71 (EV71) coxsackievirus A16, while A6 (CA6). In recent years, worldwide outbreaks of CA6-associated have dramatically increased, although the pathogenic mechanism CA6 still unclear. EV71 has been established to induce caspase-dependent apoptosis, but in this study, we demonstrate that infection promotes distinct pathway cell death involves loss...
Triple negative breast cancer (TNBC) that has low survival rate and prognosis due to its heterogeneity lack of reliable molecular targets for effective targeted therapy. Therefore, finding new biomarkers is crucial the treatment TNBC. The experimental data from Cancer Genome Atlas database (TCGA).First, key genes associated with TNBC were screened used analysis using a single-factor COX regression combined three algorithms: LASSO, RF SVM-RFE. Multi-factor was then construct risk prognostic...
Abstract Background: DCC-3014 is an orally administered kinase inhibitor targeting the switch pocket of colony-stimulating factor 1 receptor (CSF1R). exhibits approximately 100-fold selectivity from kinases homologous to CSF1R, such as KIT, and greater against 300 other human kinases. Tumor-associated macrophages (TAMs) are dependent on CSF1R activity for proliferation maintenance immunosuppressive phenotype. TAMs known enable tumor cells escape immune surveillance. designed exhibit...
11511 Background: GIST is driven by primary and secondary driver mutations in KIT/PDGFRα cell-free tumor (ct) DNA may provide the opportunity to assess disease status response therapy. The pan-KIT/PDGFRα switch control inhibitor DCC-2618 has demonstrated durable heavily pre-treated pts ongoing Phase 1 study (NCT02571036). Methods: Pts with advanced were treated either escalation stage or expansion cohorts of oral DCC-2618. Tissue liquid biopsies performed tested via next generation...
Abstract Background: Rebastinib is an orally administered, kinase inhibitor targeting the switch pocket of tunica interna endothelial cell (TIE2). TIE2 primarily expressed in cells, playing a role angiogenesis. In addition, subset macrophages, expressing macrophages (TEMs), which have pro-angiogenic, pro-metastatic, and immunosuppressive properties. Accumulating evidence suggests that chemotherapies, such as paclitaxel, increase recruitment activity TEMs, leading to chemotherapy resistance....
Abstract Objective: Ripretinib (DCC-2618) is a kinase switch control inhibitor designed to broadly inhibit KIT and PDGFRA mutations. Based on clinical activity observed in heavily pretreated patients (pts) with GIST Phase 1 study (NCT02571036), ripretinib under evaluation two 3 studies: INVICTUS (NCT03353753) ≥4th-line pts INTRIGUE (NCT03673501) 2nd-line pts, each at the recommended dose of 150 mg once daily (QD). This abstract reports updated results from escalation expansion phases for...
Pseudolaric acid B (PAB) is a diterpene‑type acid isolated from the root and trunk bark of <em>Pseudolarix kaempferi</em> Gordon <em>Pinaceae</em> family that has been demonstrated to induce apoptosis in various cell lines autophagy certain including murine fibrosarcoma L929, human thyroid squamous carcinoma SW579 lung fibroblast MRC5 cells. However, rhabdomyosarcoma RD cells, which are derived most common soft tissue sarcoma children represent high‑grade neoplasm skeletal...
Numerous viruses manipulate host factors for viral production. We demonstrated that human enterovirus A71 (EVA71), a primary causative agent hand, foot, and mouth disease (HFMD), increased the level of DNA damage response (DDR) marker γ-H2AX. DDR is primarily mediated by ataxia telangiectasia mutated (ATM), ATM Rad3-related (ATR), or DNA-dependent protein kinase (DNA-PK) pathways. Upregulation γ-H2AX EVA71 was dependent on ATR but not DNA-PK pathway. As nuclear factor, there no previous...
Abstract Hepatocellular carcinoma (HCC), the 5th most frequent cancer worldwide, has a 5-year survival rate of 14% because it is difficult to diagnose at its curative stages. The goal this project determine if detection clonally expanded HBV DNA integration sites can be used as marker for early related HCC (HBV-HCC) in order improve prognosis Hepatitis B virus (HBV) infections are associated with over 80% cases worldwide. Upon infection, genome integrates into host chromosome random site,...